What class is eptifibatide in?
Eptifibatide belongs to the antiplatelet drug class known as glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors. It blocks the platelet receptor GP IIb/IIIa, which helps prevent platelets from aggregating and forming clots [1].
How does it work compared with other antiplatelet drugs?
Because eptifibatide targets the GP IIb/IIIa receptor on platelets, it is considered a direct, short-acting platelet aggregation inhibitor. Other common antiplatelet classes (like P2Y12 inhibitors and aspirin) act through different pathways upstream of platelet activation rather than directly blocking GP IIb/IIIa-mediated cross-linking [1].
What conditions is this drug class used for?
GP IIb/IIIa inhibitors such as eptifibatide are used in acute, high-risk settings where preventing platelet-driven clot formation matters, especially in certain patients with acute coronary syndromes and in conjunction with procedures like percutaneous coronary intervention (PCI) [1].
What’s the typical clinical risk to watch with this class?
The main safety concern with GP IIb/IIIa inhibitors is bleeding risk, since blocking platelet aggregation can make it harder for the body to form clots [1].
Is there more than one drug in the GP IIb/IIIa class?
Yes. Eptifibatide is one agent in the GP IIb/IIIa inhibitor class; other drugs in the same category also block platelet GP IIb/IIIa and share similar mechanisms and bleeding risks [1].
Sources
[1] https://www.drugs.com/monograph/eptifibatide.html